As the world's leading provider of generic drugs, Teva Pharmaceuticals understands the importance of making safe, quality medications accessible and affordable.   We believe that every one of us should have access to quality medicine that helps manage disease, fights infection, or simply improves overall health.

Around 200 million people worldwide take one of our medicines every day.1 In the United States, where Teva is the leading generic pharmaceutical company, one out of every nine prescriptions is filled by a Teva product.2 In the UK it is one out of every six3 and in Canada it is one out of every six.4 In addition, many prescription drugs made by other companies include active pharmaceutical ingredients produced by Teva.

With generic products, patients usually pay less while receiving the same medicine that is in the brand name product prescribed by their doctors. Generic medicines cost, on average, 80–85% less than brand-name drugs.5

Teva’s generic products support healthcare systems. Patients and healthcare providers saved hundreds of  billions of dollars in the last decade by choosing Teva’s prescription generic medicine over more expensive brands.5

Our global footprint is critical to ensuring that our patients have access to our medicines. Teva has the largest supply chain of any pharmaceutical company and our network of 43,000 employees and 70 global manufacturing sites work around the clock to make sure our medicines reach patients in over 60 countries across six continents.6 Every hour there is a plane in the air, a ship on the seas or a truck on the road delivering Teva’s generic medicines to pharmacies and hospitals around the world.

We are committed to creating quality, affordable medicines for more people in more places around the world. Our scientists are currently developing over 800 generic medicines7 that aim to increase access to treatments that can improve patients’ health and save healthcare providers billions. Teva continues to strive for a healthier world.

View our Frequently Asked Questions to learn more about generic medicines.

_______________________________________________________________

References:

1 Internal analyses conducted by Global Insights, Access & Technologies estimating number of Teva consumers. Ref 1 dated August 2016; Ref 2 dated April 2019

2 Based on IQVIA NPA - Generic TRx by Corp – MAT March 2019

3 Data on File: UKMED180180 vCertification 1.2 DOF 148a 1 in 6 prescription packs

4 IQVIA Source CDH Compuscript MAT 2019.04

5 MGA Economic Impact Study dated June 2017

Association for Accessible Medicines 2019 Generic Drug and Biosimilars Access & Savings in the U.S. Report: https://accessiblemeds.org/resources/blog/2019-generic-drug-and-biosimilars-access-savings-us-report. Data source for number of products & facilities: Teva Global Operations

7 Data source: Global Generic R&D Pipeline as of  June 2019